alpha-aminopyridine has been researched along with Disease Exacerbation in 86 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.16) | 18.2507 |
| 2000's | 3 (3.49) | 29.6817 |
| 2010's | 72 (83.72) | 24.3611 |
| 2020's | 10 (11.63) | 2.80 |
| Authors | Studies |
|---|---|
| Arahata, Y; Bundo, M; Ikenuma, H; Ito, K; Iwata, K; Kato, T; Kimura, Y; Nakamura, A; Nihashi, T; Okamura, N; Sakurai, K; Sakurai, T; Suzuki, K; Takeda, A; Washimi, Y; Yamaoka, A; Yanai, K | 1 |
| Kinoshita, T; Sakurada, A; Sakurai, T; Seki, H; Shimizu, K | 1 |
| Bai, H; Zeng, S; Zou, M | 1 |
| Abbattista, A; Bauer, TM; Felip, E; Gainor, JF; Johnson, ML; Navarro, A; Peltz, G; Pithavala, YK; Shaw, AT; Thurm, H | 1 |
| André, F; Catron, K; Chan, A; Chapman, SC; Gainford, MC; Goel, S; Hilton, JF; Im, SA; Johnston, SR; Kim, SB; Price, GL; Ricci, F; Tolaney, SM; Troso-Sandoval, TA; Wardley, AM; Yang, Z; Zambelli, S | 1 |
| Fortescue, R; Janjua, S; Poole, P | 1 |
| Abely, M; Biouhee, T; Bui, S; Burgel, PR; Chiron, R; Corvol, H; Dehillotte, C; Durieu, I; Hubert, D; Lemonnier, L; Macey, J; Marguet, C; Martin, C; Mely, L; Munck, A; Murris-Espin, M; Paillasseur, JL; Porzio, M; Prevotat, A; Reix, P; Sermet-Gaudelus, I; Silva, JD | 1 |
| Jerusalem, G; Neven, P; Sonke, GS | 1 |
| Arteaga, CL; Barroso-Sousa, R; Bermejo, B; Cantley, LC; Céliz, P; Ciruelos, E; Garrido-Castro, AC; Gavilá, J; Guo, H; Krop, IE; Li, Y; Lin, NU; Mills, GB; Paré, L; Prat, A; Rodon, J; Saura, C; Savoie, J; Serra, V; Solit, DB; Villagrasa, P; Winer, EP; Xu, Z | 1 |
| Raol, YH; Sampath, D; Valdez, R; White, AM | 1 |
| Mayer-Hamblett, N; VanDevanter, DR | 1 |
| Casciaro, R; Costa, S; Dang, P; Majo, F; Ros, M | 1 |
| Berg, T; Borlak, J; van Bömmel, F | 1 |
| Albert, RK; Anzueto, A; Calverley, PMA; Criner, GJ; Hurst, JR; Krishnan, JA; Miravitlles, M; Papi, A; Rabe, KF; Rigau, D; Sliwinski, P; Tonia, T; Vestbo, J; Wedzicha, JA; Wilson, KC | 1 |
| Cho, J; Furumoto, S; Ido, T; Jeong, HJ; Kang, H; Kang, JM; Lee, H; Lee, KM; Lee, SY; Lee, YB; Na, DL; Noh, Y; Okamura, N; Park, KH; Seo, S; Seong, JK; Shin, DH; Villemagne, VL; Woo, SH; Yanai, K; Yeon, BK | 1 |
| Chong, J; Leung, B; Poole, P | 1 |
| Doi, T; Hewes, B; Ishikawa, N; Kakizume, T; Tajima, T; Yamada, Y | 1 |
| Bachelot, T; Chan, S; Farci, D; Han, HS; Jerusalem, G; Kong, A; Massacesi, C; Mouhaër, SL; Pistilli, B; Pluard, T; Robinson, D; Saura, C; Tomaso, ED; Urban, P; Urruticoechea, A | 1 |
| Bachelot, T; Blau, S; Bordonaro, R; Ciruelos, E; Csőszi, T; Decker, T; Dharan, B; Di Leo, A; Egle, D; El-Hashimy, M; Janni, W; Johnston, S; Kalev, D; Lee, KS; Lønning, PE; Mouret-Reynier, MA; O'Regan, R; Schirone, A; Sellami, D; Tjan-Heijnen, VCG; Weber, D | 1 |
| Amer, AO; Badr, A; Caution, K; Cormet-Boyaka, E; Dakhlallah, D; Hall-Stoodley, L; Hamilton, K; Hayes, D; Kirkby, SE; Klamer, BG; Kopp, BT; Krause, K; McCoy, KS; Parinandi, NL; Partida-Sanchez, S; Robledo-Avila, F; Shrestha, C; Tazi, MF; Tumin, D; Zhang, X | 1 |
| Connett, GJ; Hammond, JA | 1 |
| Fan, Y; Guo, F; Song, D; Sun, Q; Wang, J; Wang, L; Zhang, D; Zhang, Q; Zhang, W | 1 |
| Balestra, V; Bordi, P; Facchinetti, F; Gnetti, L; Majori, M; Silini, EM; Silva, M; Tiseo, M; Ventura, L | 1 |
| Hecht, KA; Selby, C | 1 |
| Benisvy, D; Borson-Chazot, F; Bournaud, C; Dantony, E; de la Fouchardière, C; Decaussin-Petrucci, M; Delahaye, A; Do Cao, C; Eberle, MC; Illouz, F; Klein, M; Lapras, V; Lasolle, H; Leboulleux, S; Lopez, J; Niccoli, P; Rabilloud, M; Schlumberger, M; Tabarin, A; Wassermann, J | 1 |
| Boyle, MP; Jiang, JG; Konstan, MW; Marigowda, G; McColley, SA; Ramsey, BW; Rubin, JL; Stuart Elborn, J; Vera-Llonch, M; Wainwright, CE; Waltz, D | 1 |
| Davies, A; Gibson, D; Kiff, C; Purkayastha, D; Ruiz, S; Varol, N | 1 |
| Bonk, MP; Hadjiliadis, D; Rey, MM | 1 |
| Bøttcher, TM; Cold, S; Jensen, AB | 1 |
| Alexa, I; Alexa-Stratulat, T; Antohe, I; Antoniu, S; Arghir, O; Grigorescu, C | 1 |
| De Angelis, C; Ekinci, E; Flajc, G; Liu, X; Rascon, K; Trivedi, MV | 1 |
| Flume, PA; Kosinski, M; Marigowda, G; Quittner, AL; Suthoff, ED | 1 |
| Ishii, K; Kubota, I; Shirakawa, O; Takaya, M | 1 |
| Agar, NYR; Alexander, BM; Basu, SS; Batchelor, TT; Beroukhim, R; Brown, LE; Chang, SM; Chi, AS; Cloughesy, TF; Colman, H; de Groot, JF; DeAngelis, LM; Dunn, IF; Gaffey, SC; Gilbert, MR; Haidar, S; Heath, JR; Horky, LL; Huse, JT; Kim, J; Koul, D; Kuhn, JG; Lee, EQ; Ligon, AH; Ligon, KL; Martinez-Ledesma, JE; McCluskey, CS; Mellinghoff, IK; Nayak, L; Omuro, AM; Park, MA; Pelton, K; Prados, MD; Ramkissoon, S; Reardon, DA; Rinne, ML; Roberts, TM; Touat, M; Wei, W; Wen, PY; Wu, S; Young, GS; Yung, WKA; Zhao, JJ | 1 |
| Algazi, AP; Daud, A; Munster, PN; Ortiz-Urda, S; Pelayo, A; Posch, C; Rotow, J | 1 |
| De Wachter, E; Vanderhelst, E; Verbanck, S; Vincken, S | 1 |
| Abbattista, A; Bauer, TM; Besse, B; Camidge, DR; Chiari, R; Clancy, JS; Felip, E; Gadgeel, SM; Kao, S; Li, S; Lin, CC; Martini, JF; Ou, SI; Riely, GJ; Satouchi, M; Shaw, AT; Solomon, BJ; Soo, RA; Thurm, H | 1 |
| Aoki, M; Arai, H; Baba, T; Ezura, M; Funaki, Y; Furukawa, K; Furumoto, S; Harada, R; Hasegawa, T; Hiraoka, K; Ishiki, A; Iwata, R; Kikuchi, A; Kobayashi, J; Kobayashi, M; Kudo, Y; Mugikura, S; Nakashima, I; Okamura, N; Oshima, R; Sugeno, N; Takeda, A; Taki, Y; Tano, O; Tashiro, M; Watanuki, S; Yanai, K; Yoshida, S | 1 |
| Bratcher, PE; Chioccioli, M; Cicuta, P; Feriani, L; Kotar, J | 1 |
| Balfour-Lynn, IM | 1 |
| Bredenbröker, D; Calverley, PMA; Cooke, GE; Goehring, UM; Kowey, PR; Lakkis, H; Mosberg, H; Rabe, KF; Rowe, P; White, WB; Zhu, H | 1 |
| Jenkins, C; Leuppi, J; Osthoff, M | 1 |
| Antoniu, SA | 1 |
| Dharmarajan, S; Dinavahi, SS; Nyayapathy, S; Perumal, Y; Viswanadha, S | 1 |
| Godwin, AK; Kaufman, MD; Kwon, Y; Smith, BD; Zhou, Y | 1 |
| Coyle, T | 1 |
| Bredenbröker, D; Brose, M; Calverley, PMA; Goehring, UM; Martinez, FJ; Rabe, KF; Wedzicha, JA | 2 |
| Aljawai, Y; Anderson, KC; Ghobrial, IM; Glavey, S; Huynh, D; Maiso, P; Manier, S; Mishima, Y; Moschetta, M; Munshi, NC; Pachter, J; Reagan, M; Ring, JE; Roccaro, AM; Sacco, A; Sahin, I; Tai, YT; Tam, WF; Xu, Q; Zhang, W; Zhang, Y | 1 |
| Benhamou, C; Duffield, EL; Fudman, E; Genovese, MC; Kavanaugh, A; Keystone, EC; Lampl, K; O'Brien, C; Poiley, J; Spindler, AJ; van der Heijde, DM; Weinblatt, ME | 1 |
| Amin, A; Ellis, JJ; Howe, A; Moll, K; Sun, SX | 1 |
| Burton, EA; Chartier, S; Habets, G; Jimenez-Andrade, JM; Lin, PS; Mantyh, PW; Thompson, ML; Tsai, J; West, BL | 1 |
| Jardim, JR; Stirbulov, R | 1 |
| Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK | 1 |
| Corman, S; Gao, X; Huang, X; Shorr, AF; Sun, SX; Wan, Y | 1 |
| Ardeshna, KM; Bartlett, NL; Blum, KA; Flinn, IW; Flowers, CR; Friedberg, JW; LaCasce, AS; Mitchell, P; Shustov, AR; Skolnik, JM; Thress, KS; Zheng, F | 1 |
| Mayer, M | 1 |
| Anto-Michel, N; Blanz, KD; Bode, C; Braddock, M; Dufner, B; Geis, S; Gerhardt, LM; Gilsbach, R; Härdtner, C; Hawley, S; Heidt, T; Hein, L; Hergeth, SP; Hilgendorf, I; Hoppe, N; Kornemann, J; Libby, P; Lindau, A; McPheat, W; Robbins, CS; Stachon, P; Swirski, FK; von zur Mühlen, C; Willecke, F; Wolf, D; Zirlik, A; Zou, J | 1 |
| Bateman, ED; Goehring, UM; Richard, F; Watz, H | 1 |
| Ho, M; Jenkins, M; Landewé, R; Markusse, IM; van der Heijde, D; Wolterbeek, R | 1 |
| Hodgden, JD; Huser, JM | 1 |
| DeNardo, DG; Hawkins, WG; Hegde, S; Herndon, JM; Jiang, H; Knolhoff, BL; Meyer, MA; Nywening, TM; Pachter, JA; Shapiro, IM; Wang-Gillam, A; Weaver, DT; Zhu, Y | 1 |
| Cai, Q; Dai, X; Shao, N; Yang, M; Yuan, L | 1 |
| Anzueto, A; Martinez, FJ; McIvor, A; Pizzichini, E; Rabe, KF; Rennard, SI; Sethi, S; Siddiqui, S; Zhu, H | 1 |
| Alagappan, VK; Anzueto, A; Martinez, FJ; McIvor, A; Miller, CJ; Pizzichini, E; Rabe, KF; Reisner, C; Rekeda, L; Rennard, SI; Sethi, S; Siddiqui, S; Zetterstrand, S | 1 |
| Burki, TK | 1 |
| Goss, CH; Huang, X; Konstan, MW; Lubarsky, B; Marigowda, G; Mayer-Hamblett, N; McKone, EF; Millar, SJ; Morgan, W; Moss, RB; Pasta, DJ; Rubin, J; Sawicki, GS; Tian, S; Waltz, D | 1 |
| Arnaud, A; Berton-Rigaud, D; Fabbro, M; Favier, L; Floquet, A; Foa, C; Heudel, PE; Joly, F; Kalbacher, E; Kaminsky, MC; Lesoin, A; Lortholary, A; Meunier, J; Priou, F; Ray-Coquard, I; Roche-Forestier, S; Roemer-Becuwe, C; Selle, F; Tazi, Y; Treilleux, I; You, B | 1 |
| Donaldson, GC; Goehring, UM; Mackay, AJ; Nip, TK; Patel, ARC; Prasad, N; Sapsford, RJ; Singh, R; Wedzicha, JA | 1 |
| Althage, A; Beyer, C; Chen, CW; Cole, SH; Distler, JH; Gergely, P; Harris, JL; Hsieh, MH; Li, C; Liu, J; Maier, C; Meeusen, S; Ng, N; Pan, S; Schett, G; Seidel, HM; Svensson, EC; Trinh-Minh, T; Xu, X | 1 |
| Ali, SM; Fernandez-Rocha, MY; Gitlitz, BJ; Lee, TK; Milliken, J; Ou, SI; Pavlick, D; Schrock, AB; Young, L; Zhu, VW | 1 |
| Bähr, M; Diem, R; Neusch, C; Otto, M; Pehlke, JR; Sättler, MB; Williams, SK | 1 |
| Asada, M; Funasaka, S; Matsushima, T; Nakagawa, T; Obaishi, H; Shirotori, S; Takahashi, K; Tohyama, O; Yamaguchi, A | 1 |
| Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C | 1 |
| Chuang, PY; Deng, Y; He, JC; Klotman, PE; Liu, R; Mallipattu, SK; Wu, Y; Zhong, Y | 1 |
| Vetter, C | 1 |
| Del Pino-Montes, J; Gómez-Castro, S; Hidalgo, C; López, R; Montilla Morales, C; Sánchez, M | 1 |
| Almagro, P; Ancochea, J; Calle, M; López-Campos, JL; Miravitlles, M; Molina, J; Piñera, P; Quintano, JA; Riesco, JA; Simón, A; Soler-Cataluña, JJ; Soriano, JB; Trigueros, JA | 1 |
| Beume, R; Dieckmann, A; Hanauer, G; Heuser, A; Kaessner, N; Kley, HP; Knaack, D; Vollert, S; Weiss-Haljiti, C | 1 |
| Calverley, PM; Fabbri, LM; Goehring, UM; Martinez, FJ; Rabe, KF | 1 |
| Lone, NA; Oba, Y | 1 |
| Haefliger, S; Ledderhose, S; Radford, M; Samyshkin, Y; Schlunegger, M | 1 |
| Keogh, GF; Knight, RS; Rydzewska, LH; Stewart, LA | 1 |
| Bahjat, FR; Baluom, M; Cassafer, G; Chang, B; Daikh, DI; Grillo, S; Grossbard, EB; Payan, DG; Pine, PR; Reitsma, A; Zhao, FF | 1 |
| Hohlfeld, R; Zimmermann, C | 1 |
17 review(s) available for alpha-aminopyridine and Disease Exacerbation
| Article | Year |
|---|---|
Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Diarrhea; Disease Progression; Headache; Humans; Pulmonary Disease, Chronic Obstructive | 2022 |
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Diarrhea; Disease Progression; Forced Expiratory Volume; Humans; Middle Aged; Nitriles; Peak Expiratory Flow Rate; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Thiazoles; Vital Capacity | 2020 |
Ribociclib plus fulvestrant in the treatment of breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Progression-Free Survival; Purines; Randomized Controlled Trials as Topic; Survival Rate | 2021 |
Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
Topics: Aminophenols; Aminopyridines; Anti-Bacterial Agents; Benzodioxoles; Chloride Channel Agonists; Clinical Trials as Topic; Comparative Effectiveness Research; Cystic Fibrosis; Disease Progression; Drug Combinations; Humans; Pseudomonas Infections; Quinolones; Standard of Care; Treatment Outcome | 2017 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Progression; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2017 |
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Aminopyridines; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2 | 2019 |
Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Drugs, Investigational; Everolimus; Female; Humans; Molecular Targeted Therapy; Piperazines; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2019 |
Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Hospitalization; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2019 |
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Premenopause; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2019 |
Clinical papers of the year 2018 - Cystic fibrosis.
Topics: Administration, Inhalation; Aminophenols; Aminopyridines; Anti-Bacterial Agents; Azithromycin; Benzodioxoles; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Chloride Channel Agonists; Cough; Cross Infection; Cystic Fibrosis; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Indoles; Lung Transplantation; Microbiological Techniques; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Nebulizers and Vaporizers; Proton Pump Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Randomized Controlled Trials as Topic; Saline Solution, Hypertonic; Specimen Handling; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 2020 |
Chronic obstructive pulmonary disease--a treatable disease.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Benzamides; Breathing Exercises; Bronchodilator Agents; Cyclopropanes; Disease Progression; Humans; Muscarinic Antagonists; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pneumonectomy; Pulmonary Disease, Chronic Obstructive; Smoking Cessation | 2013 |
Clinical Question: In adults with COPD does roflumilast reduce the frequency of exacerbations compDared to standard therapies aIone?
Topics: Adult; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Humans; Patient Acuity; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests | 2016 |
Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
Topics: Aminopyridines; Benzamides; Chi-Square Distribution; Cyclopropanes; Disease Progression; Forced Expiratory Volume; Humans; Lung; Odds Ratio; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Severity of Illness Index; Spirometry; Treatment Outcome; Vital Capacity | 2016 |
[New therapeutic targets in psoriatic arthritis].
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antirheumatic Agents; Arthritis, Psoriatic; Bone Remodeling; Clinical Trials, Phase III as Topic; Cyclic AMP; Cytokines; Denosumab; Disease Progression; Drug Resistance; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Janus Kinases; Lymphocyte Activation; Lymphocyte Depletion; Molecular Targeted Therapy; Morpholines; Oxazines; Phosphodiesterase 4 Inhibitors; Pyridines; Pyrimidines; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Female; Humans; Lung; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Treatment Outcome | 2013 |
Systematic review of therapeutic interventions in human prion disease.
Topics: Aminopyridines; Analgesics; Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Disease Progression; Drug Evaluation, Preclinical; Humans; Neuropharmacology; Prion Diseases; Survival Rate; Treatment Failure | 2008 |
['Fatigue' in multiple sclerosis].
Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis; Pemoline; Potassium Channel Blockers; Severity of Illness Index | 1999 |
24 trial(s) available for alpha-aminopyridine and Disease Exacerbation
| Article | Year |
|---|---|
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Incidence; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Pyrazoles | 2020 |
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Benzimidazoles; Brazil; Breast Neoplasms; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Humans; Middle Aged; North America; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Signal Transduction; Time Factors; Trastuzumab | 2020 |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Patient Safety; Protein Kinase Inhibitors; Proteomics; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.
Topics: Adult; Aminopyridines; Disease Progression; Drug Administration Schedule; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Purines; Sample Size; Treatment Outcome | 2018 |
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Trastuzumab | 2018 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pilot Projects; Progression-Free Survival; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2018 |
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV
Topics: Adolescent; Adult; Aged; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Disease Progression; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Quinolones; Respiratory Function Tests; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Disease Progression; Drug Combinations; Female; Humans; Male; Quality of Life; Quinolones; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Enzyme Activation; Female; Glioblastoma; Humans; Male; Middle Aged; Morpholines; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Time Factors | 2019 |
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Decision-Making; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Risk Factors; Time Factors | 2019 |
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prevalence; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Switzerland; Treatment Outcome | 2013 |
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Topics: Adult; Aminopyridines; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Maximum Tolerated Dose; Methotrexate; Middle Aged; Morpholines; Oxazines; Patient Safety; Prognosis; Pyridines; Pyrimidines; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Organoplatinum Compounds; Phosphoinositide-3 Kinase Inhibitors | 2015 |
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Recurrence; Syk Kinase; Time Factors; Treatment Outcome; United States | 2016 |
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma.
Topics: Acetates; Aged; Aged, 80 and over; Aminopyridines; Anti-Asthmatic Agents; Asthma; Benzamides; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Leukocyte Count; Leukotriene Antagonists; Male; Middle Aged; Quinolines; Risk Factors; Severity of Illness Index; Spirometry; Sulfides; Treatment Outcome | 2016 |
Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis.
Topics: Adult; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Linear Models; Male; Middle Aged; Morpholines; Oxazines; Pyridines; Pyrimidines; Radiography; Treatment Outcome | 2016 |
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Severity of Illness Index | 2016 |
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cough; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Forced Expiratory Volume; Homozygote; Humans; Lung; Male; Mutation; Quinolones; Time; Treatment Outcome; Young Adult | 2017 |
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Disease Progression; Endometrial Neoplasms; Female; Humans; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Recurrence; Treatment Outcome | 2017 |
Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Leukocyte Count; London; Male; Middle Aged; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sputum; Treatment Outcome | 2017 |
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Topics: Adrenal Cortex Hormones; Adult; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Poisson Distribution; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Severity of Illness Index; Treatment Outcome | 2012 |
Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Diarrhea; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Humans; Incidence; Male; Middle Aged; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Weight Loss | 2013 |
45 other study(ies) available for alpha-aminopyridine and Disease Exacerbation
| Article | Year |
|---|---|
Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
Topics: Aged; Alzheimer Disease; Aminopyridines; Amnesia; Aniline Compounds; Brain; Cognitive Dysfunction; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Severity of Illness Index; tau Proteins; Thiazoles | 2022 |
Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Japan; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Treatment Outcome | 2022 |
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Disease Progression; Drug Combinations; Female; France; Humans; Male; Quinolones; Respiratory Function Tests | 2021 |
Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy.
Topics: Aminopyridines; Animals; Animals, Newborn; Anticonvulsants; Brain; Disease Models, Animal; Disease Progression; Electrocorticography; Hypoxia-Ischemia, Brain; Injections, Intraperitoneal; Male; Phenobarbital; Random Allocation; Rats, Sprague-Dawley; Seizures; Time Factors | 2017 |
Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Drug Therapy, Combination; Forced Expiratory Volume; Homozygote; Humans; Italy; Mutation; Quinolones; Surveys and Questionnaires; Treatment Outcome | 2018 |
N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury.
Topics: Acetylcysteine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; Antidotes; Biomarkers; Cells, Cultured; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Glutathione; Hepatocytes; Humans; Infusions, Intravenous; Liver; Liver Transplantation; Male; Middle Aged; Prednisolone; Recovery of Function; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Fluoroquinolones; Humans; Macrolides; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Secondary Prevention; Societies, Medical; United States | 2017 |
Tau positron emission tomography using [
Topics: Aged; Alzheimer Disease; Aminopyridines; Amnesia; Brain; Cognitive Dysfunction; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Severity of Illness Index; tau Proteins | 2017 |
The expression of Mirc1/Mir17-92 cluster in sputum samples correlates with pulmonary exacerbations in cystic fibrosis patients.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Chloride Channel Agonists; Correlation of Data; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Drug Monitoring; Female; Gene Expression Profiling; Humans; Male; MicroRNAs; Nerve Tissue Proteins; Quinolones; Respiratory Function Tests; Respiratory System; RNA, Long Noncoding; Sputum | 2018 |
The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Female; Homozygote; Humans; Lung; Membrane Transport Modulators; Mutation; Patient Care Management; Quinolones; Respiratory Function Tests; Symptom Flare Up; Treatment Outcome | 2018 |
Hypermethylated CD36 gene affected the progression of lung cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; CD36 Antigens; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Invasiveness; Xenograft Model Antitumor Assays | 2018 |
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Disease Progression; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Prognosis; Pyrazoles; Sarcoidosis | 2019 |
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Topics: Administration, Inhalation; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; United Kingdom | 2018 |
Cystic Fibrosis: Emerging Understanding and Therapies.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chronic Disease; Combined Modality Therapy; Comprehension; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Management; Disease Progression; Drug Approval; Female; Genetic Predisposition to Disease; Humans; Lung Transplantation; Male; Prognosis; Quinolones; Risk Assessment; Severity of Illness Index; Survival Analysis; United States; United States Food and Drug Administration | 2019 |
Progression of logopenic aphasia to frontotemporal dementia in an amyloid β-negative and
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Aphasia; Brain; Disease Progression; Female; Frontotemporal Dementia; Frontotemporal Lobar Degeneration; Humans; Middle Aged; Positron-Emission Tomography; Quinolines; Radioactive Tracers; tau Proteins | 2019 |
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600
Topics: Aminopyridines; Disease Progression; Humans; Melanoma; Morpholines; Mutation; Proto-Oncogene Proteins B-raf; Vemurafenib | 2019 |
Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Breath Tests; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Exhalation; Female; Humans; Male; Nitric Oxide; Prospective Studies; Quinolones; Young Adult | 2019 |
Longitudinal changes in
Topics: Aged; Aminopyridines; Basal Ganglia Diseases; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Tauopathies | 2019 |
Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells.
Topics: Algorithms; Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cilia; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Epithelial Cells; Genotype; Humans; Microscopy; Oscillometry; Phenotype; Quinolones; Video Recording | 2019 |
Phenotype/endotype-driven therapy in COPD: potential economic implications.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Costs; Forced Expiratory Volume; Humans; Lung; Patient Selection; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Treatment Outcome | 2013 |
Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease.
Topics: Adenine; Aminopyridines; Benzamides; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclopropanes; Disease Progression; Humans; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Neutrophils; Nicotiana; Phosphodiesterase 4 Inhibitors; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Alveoli; Pulmonary Disease, Chronic Obstructive; Quinazolines; Smoke; U937 Cells | 2014 |
Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Topics: Aminopyridines; Anilides; Animals; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Female; Fibroblasts; Hepatocyte Growth Factor; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-met; Random Allocation; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Evidence roflumilast reduces severe exacerbations?
Topics: Aminopyridines; Benzamides; Disease Progression; Female; Humans; Male; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Response.
Topics: Aminopyridines; Benzamides; Disease Progression; Female; Humans; Male; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Pyk2 promotes tumor progression in multiple myeloma.
Topics: Aminopyridines; Animals; beta Catenin; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Progression; Female; Focal Adhesion Kinase 2; Gene Expression Regulation, Enzymologic; Green Fluorescent Proteins; HEK293 Cells; Humans; Immunoblotting; Luminescent Measurements; Mice, SCID; Multiple Myeloma; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Survival Analysis; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2014 |
Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Aminopyridines; Benzamides; Chi-Square Distribution; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Costs; Female; Health Resources; Hospital Costs; Hospitalization; Humans; Linear Models; Male; Medicare Part C; Middle Aged; Models, Economic; Multivariate Analysis; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Time Factors; Treatment Outcome; United States | 2015 |
Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.
Topics: Aminopyridines; Analgesics; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Dogs; Formaldehyde; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pain; Pain Measurement; Prostatic Neoplasms; Protein Kinases; Pyrroles; Rats; Rats, Sprague-Dawley | 2015 |
Roflumilast in COPD: a Brazilian perspective.
Topics: Aminopyridines; Benzamides; Brazil; Cyclopropanes; Disease Progression; Humans; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2015 |
A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
Topics: Aged; Ambulatory Care; Aminopyridines; Benzamides; Cost of Illness; Cyclopropanes; Disease Progression; Female; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Retrospective Studies; Symptom Flare Up; United States | 2015 |
Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Body Mass Index; Cystic Fibrosis; Data Interpretation, Statistical; Disease Progression; Drug Approval; Drug Combinations; Drug Costs; Evidence-Based Medicine; Humans; Lung; Quinolones; Surveys and Questionnaires; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression.
Topics: Aminopyridines; Animals; Atherosclerosis; Cell Adhesion; Cells, Cultured; Disease Progression; Drug Evaluation, Preclinical; Female; Intracellular Signaling Peptides and Proteins; Macrophages; Mice; Monocytes; Morpholines; Myelopoiesis; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Random Allocation; Syk Kinase | 2016 |
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Topics: Aminopyridines; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Fibrosis; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; Immunotherapy; Immunotherapy, Adoptive; Mice; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Escape; Tumor Microenvironment | 2016 |
Ribociclib in HR-positive, HER2-negative breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2016 |
Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling.
Topics: Acyltransferases; Aminopyridines; Animals; Bleomycin; Disease Models, Animal; Disease Progression; Female; Fibrosis; Graft vs Host Disease; Membrane Proteins; Mice, Inbred BALB C; Piperazines; Protein Serine-Threonine Kinases; Pulmonary Fibrosis; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Scleroderma, Localized; Scleroderma, Systemic; Skin; Transforming Growth Factor beta; Wnt Signaling Pathway | 2017 |
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Crizotinib; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Retinoblastoma Binding Proteins; Small Cell Lung Carcinoma; Ubiquitin-Protein Ligases | 2017 |
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.
Topics: Aminopyridines; Animals; Autoimmune Diseases; Cell Survival; Cells, Cultured; Cytoprotection; Disease Progression; Drug Therapy, Combination; Evoked Potentials, Visual; Female; Inflammation; Interferon-beta; Ion Channel Gating; Neuroprotective Agents; Optic Nerve; Optic Neuritis; Potassium Channels, Inwardly Rectifying; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred BN; Rats, Wistar; Retinal Ganglion Cells | 2008 |
E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Progression; Female; Humans; Mice; Neoplasms, Experimental; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
New evidence in pulmonary and preventive medicine.
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Benzamides; Breast Neoplasms; Bronchodilator Agents; Cyclopropanes; Disease Progression; Early Detection of Cancer; Evidence-Based Medicine; Female; Humans; Papillomavirus Vaccines; Preventive Medicine; Primary Prevention; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Scopolamine Derivatives; Secondary Prevention; Tiotropium Bromide; Uterine Cervical Neoplasms | 2010 |
Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure.
Topics: AIDS-Associated Nephropathy; Aminopyridines; Animals; Benzamides; Benzoates; Cell Differentiation; CREB-Binding Protein; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Cytoprotection; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Kidney Tubules; Male; Mice; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Phosphorylation; Proteinuria; Receptors, Retinoic Acid; Renal Insufficiency; Retinoic Acid Receptor alpha; Signal Transduction; Tetrahydronaphthalenes; Time Factors | 2012 |
[New goals in COPD treatment. From symptom control to prevention of exacerbations].
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Humans; Long-Term Care; Phosphodiesterase 4 Inhibitors; Prognosis; Pulmonary Disease, Chronic Obstructive | 2011 |
Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.
Topics: Adrenal Cortex Hormones; alpha 1-Antitrypsin; Aminopyridines; Anti-Bacterial Agents; Asthma; Benzamides; Bronchitis; Bronchodilator Agents; Chronic Disease; Comorbidity; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Expectorants; Humans; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Respiratory System Agents; Severity of Illness Index; Spain; Theophylline | 2012 |
The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.
Topics: Administration, Oral; Aminopyridines; Animals; Benzamides; Blood Glucose; Cyclopropanes; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Female; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Mice; Mice, Mutant Strains; Phosphodiesterase 4 Inhibitors | 2012 |
Roflumilast: doubtful efficacy but clear harms in COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Drug Approval; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2013 |
Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cohort Studies; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Hospitalization; Humans; Life Expectancy; Male; Markov Chains; Middle Aged; Models, Econometric; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Severity of Illness Index; Switzerland | 2013 |
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Topics: Administration, Oral; Aminopyridines; Animals; Disease Progression; Lupus Erythematosus, Systemic; Mice; Mice, Inbred BALB C; Mice, Inbred NZB; Morpholines; Oxazines; Pyridines; Pyrimidines; Survival Rate; Time Factors | 2008 |